Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $11.94

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $11.94, but opened at $11.70. Aligos Therapeutics shares last traded at $11.65, with a volume of 832 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on Aligos Therapeutics in a research report on Monday, August 19th. They set a “buy” rating and a $75.00 price objective for the company.

Aligos Therapeutics Price Performance

The stock has a market cap of $929.51 million, a price-to-earnings ratio of -9.10 and a beta of 2.18. The business has a fifty day moving average of $12.57 and a 200 day moving average of $16.90.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The business had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same quarter in the prior year, the business posted ($10.75) EPS. On average, analysts expect that Aligos Therapeutics, Inc. will post -8.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC lifted its holdings in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in shares of Aligos Therapeutics in the fourth quarter worth $1,889,000. Opaleye Management Inc. lifted its stake in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after buying an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Aligos Therapeutics by 26.1% during the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after buying an additional 171,490 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).